Dr Assaf Raz is VP of Research and Development at Precisio Biotix Therapeutics. He obtained his PhD from Rockefeller University where he focused on the development of engineered phage lysins and related molecules to combat multidrug-resistant bacteria. At Precisio Biotix Therapeutics, he established and leads the company’s research team, driving the development of the staphylococcal lysin LYSG101 from bench to first-in-human compassionate use. Dr. Raz played a key role in securing a $2.5M out-licensing deal in China and a $1.5M grant from the Bill & Melinda Gates Foundation. He also led the development of a topical lysin formulation, currently in clinical evaluation, as well as the discovery and patenting of multiple lysin assets.